Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects
with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)